▲ +25.08% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Neuronetics in the last 3 months. The average price target is $19.25, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 25.08% upside from the last price of $15.39.
The current consensus among 5 contributing investment analysts is to buy stock in Neuronetics. This Buy consensus rating has held steady for over two years.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.